Journals / Türk Üroloji Dergisi/Turkish Journal of Urology / 2013 / Cilt: 39 - Sayı: 2

Antibiotic sensitivity and resistance in children with urinary tract infection in Sanliurfa

Şanlıurfa'da idrar yolu enfeksiyonu olan çocuklarda antibiyotik hassasiyeti ve direnci

Pages
106–110
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In contrast to other studies, these results suggest that co-trimoxazole should be used for children aged 0-1, and 2nd generation cephalo­ sporins should be used for the oral treatment of children aged 1-5 due to the low rate of resistance to nitro­ furantoin in patients aged over 5 years.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: This study aimed to evaluate antibiotic resistance in the province of Şanliurfa and to observe any differences.
📊
Key Findings & Data:Material and methods: The study comprised 107 children who presented at the pediatric polyclinic with complaints of urinary tract infection, were diagnosed with urinary tract infection and whose urine cultures exhibited proliferation.
💡
Conclusion & Impact:In contrast to other studies, these results suggest that co-trimoxazole should be used for children aged 0-1, and 2nd generation cephalo­ sporins should be used for the oral treatment of children aged 1-5 due to the low rate of resistance to nitro­ furantoin in patients aged over 5 years.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: This study aimed to evaluate antibiotic resistance in the province of Şanliurfa and to observe any differences. Material and methods: The study comprised 107 children who presented at the pediatric polyclinic with complaints of urinary tract infection, were diagnosed with urinary tract infection and whose urine cultures exhibited proliferation. The patients were analyzed with respect to the frequency of proliferating pathogens, sensitivity to the antibiotics used and the rates of developed resistance to the antibiotics. Results: A total of 107 patients aged between 1 year and 15 years were included in the study, encompassing 14 (13.1%) males and 93 (86.9%) females. According to the urine culture results, proliferation of Escherichia coli (E. coli) was observed in 69 (64.5%) patients, Klebsiella in 13 (12.1%) patients, Proteus mirabilis in 9 (8.4%) patients, Staphylococcus aureus in 5 (4.7%) patients, Pseudomonas aeruginosa in 5 (4.7%) patients, Acinetobacter in 3 (2.8%) patients and Enterococcus spp in 3 (2.8%) patients. For proliferating E. coli, high resistance rates to ceftriaxone (39.5%), nitrofurantoin (19.7%), ampicillin-sulbactam (64.1%), co-tri­ moxazole (41.5%), amoxicillin-clavulanate (51.7%) and cefuroxime (38.1%) were observed. Beginning with ampicillin-sulbactam and followed by amoxicillin-clavulanate, co-trimoxazole, ceftriaxone, cefuroxime and cefoxitin, resistance to agents that reduce all proliferating micro-organisms was determined. The most effective agents were determined to be imipenem, sulperazone, quinolone and aminoglycosides. Conclusion: In our region, the parenteral antibiotics that should be selected for the empirical treatment of all age groups are the aminoglycosides and 3rd generation cephalosporines. In contrast to other studies, these results suggest that co-trimoxazole should be used for children aged 0-1, and 2nd generation cephalo­ sporins should be used for the oral treatment of children aged 1-5 due to the low rate of resistance to nitro­ furantoin in patients aged over 5 years.

Özet

Amaç: Bu çalışmada Şanlıurfa ilinde antibiyotik direncini değerlendirmeyi ve farklılığı gözlemlemeyi amaçladık. Gereç ve yöntemler: Pediatri ve Üroloji polikliniğine idrar yolu enfeksiyonu yakınmalarıyla başvuran, idrar yolu enfeksiyonu tanısı konan ve idrar kültürlerinde üremesi olan 107 çocuk çalışmaya alındı. Hastalarda üreyen patojenlerin sıklığı, kullanılan antibiyotiklere karşı hassasiyet ve gelişen direnç oranları açısından incelendi. Bulgular: Yaşları 1 ile 15 arasında değişen 14’ü (%13.1) erkek, 93’ü (%86.9) kız toplam 107 hasta çalışma- ya alındı. Hastaların idrar kültürleri sonuçlarına göre 69’ünde (%64.5) Escherichia coli (E. coli), 13’ünde (%12.1) Klebsiella 9’unda (%8.4) proteus, 5’inde (%4.7) Staphylococcus aureus, 5’inde (%4.7) Pseudomo- nas aeruginosa, 3’ünde (%2.8) Acinetobacter ve 3’ünde (%2.8) Enterokok spp. üredi. E. coli üremeleri- nin %39.5’inde seftriaksona, %19.7’sinde nitrofurantoine, %64.1’inde ampisilin-sulbaktama, %41.5’inde ko-trimaksazole, %51.7’sinde amoksisilin-klavulanata, %38.1’inde sefuroksime karşı yüksek direnç sap- tandı. Üreyen tüm mikroorganizmalara karşı azalan sırayla ampisilin-sulbaktam, amoksisilin-klavulant, ko-trimaksazol, seftriakson, sefuroksim ve sefoksite karşı direnç tespit edildi. En etkili antibiyotiklerin imipenem, sulperazon, kinolon ve aminoglikozidler olduğu tespit edildi. Sonuç: Bölgemizde tüm yaş gruplarında ampirik tedavide seçilecek parenteral antibiyotikler aminogliko- zidler ve 3. kuşak sefalosporinlerdir. Diğer çalışmalardan farklı olarak oral tedavide 0-1 yaş arası hastalarda ko-trimaksazol, 1-5 yaş arası hastalarda 2. kuşak sefalosporinler, 5 yaş üstü hastalarda ise nitrofurantoin düşük direnç oranları nedeniyle seçilebileceği düşüncesindeyiz.

🔖

Cite This Article

ABUHANDAN, M., GÜZEL, B., OYMAK, Y., ÇİFTÇİ, H. (2013). Antibiotic sensitivity and resistance in children with urinary tract infection in Sanliurfa. Türk Üroloji Dergisi/Turkish Journal of Urology, Cilt: 39 - Sayı: 2, 106–110. https://ajindex.com/articles/328046

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Elder J.S. Urinary tract infection and vesicoureteral reflux. In Behrman RE, Kleigman RM, Jenson HB, eds. Nelson Textbook of Pediatrics. 19th ed. Philadelphia: Saunders Elsevier
  2. p.1829-38. [CrossRef] 2. Bagga A. Urinarytractinfections: evaluationandtreatment. İndian Pediatr 2001
  3. Sirin A, Emre S, Alpay H, Nayır A, Bilge I, Tanman F. Etiology of chronicrenalfailure in Turkishchildren. Pediatr Nephrol 1995
  4. Krasinski KM. Urinarytractinfections. In: Katz SL, Gershon AA, Wilfert CM (ed). Krugman.sInfectiousDisease of Children (9th Edition). St Louis: CV Mosby, 1998
  5. Committee on QualityImprovement. Subcommittee onUrinary- TractInfections. Practiseparameter: thediagnosis, treatment, ande- valuation of theinitial UTI in febrile infants and young children. Pediatrics 1999
  6. Gür D, Kanra G, Ceyhan M. Epidemiology and Antibiotic Rezistance of Gram-NegativeUrinary Pathogens in pediatric pati- ents. Turk J Pediatr 1999
  7. Özsüt H, Çalangu S. İdrar yolu infeksiyonları. Topçu-Wilke A, Söyletir G, Doğanay M, ed. İnfeksiyon Hastalıkları’nda. Ankara: Nobel Tıp Kitabevleri 1996:921-31. 8. Akata F. Üriner sistem infeksiyonlarında uygun antibiyotik kulla- nımı. KLİMİK Derg 2001
  8. Hryniewicz K, Szczypa K, Sulikowska A, Jankowski K, Betlejewska K, Hryniewicz W. Antibiotic susceptibility of bac- terial strains isolated from urinary tract infections in Poland. J Antimicrob Chemother 2001
  9. [CrossRef] 10. Gales AC, Jones RN, Gordon KA. Activity and spectrum of 22 anti microbial agents tested against urinary tract infection patho- gens in hospitalized patients in Latin America: report from the secondyear of the SENTRY Antimicrobial Surveillance Program (1998). J Antimicrob Chemother 2000
  10. [CrossRef] 11. Jones KV, Asscher AW. Urinary tract infection and vesicourethral reflux. In: Edelman CM (editor). Pediatric Kidney Disease, 2nd ed, Boston, Little Brown
  11. p.1943-91. 12.National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing
  12. Twelfth Informational Supplement.Approved Standard M100-S12. Wayne PA: NCCLS
  13. Rushton HG. Urinary tract infections in children. Epidemiology, eveluation and management. Pediatr Clin North Am 1997
  14. [CrossRef] 14. Adjei O, Opoku C. Urinary trac tinfections in Africaninfants. Int J Antimicrob Agents 2004
  15. [CrossRef] 15.Larcombe J. Urinary tract infection in children. BMJ 1999